Advertisement

Topics

FDA Nod For Ipsen, XNCR On Watch, Results MAGNIFY CELG's R2 Regimen

19:53 EDT 18 Jun 2017 | RTTNews

Today's Daily Dose brings you news about Celgene's MAGNIFY study results; FDA approval of Ipsen's expanded use of Dysport; Genmab getting milestone payment after FDA approves expanded use of Darzalex and encouraging trial results of Xencor's XmAb5871 in patients with active IgG4-Related Disease.

Original Article: FDA Nod For Ipsen, XNCR On Watch, Results MAGNIFY CELG's R2 Regimen

NEXT ARTICLE

More From BioPortfolio on "FDA Nod For Ipsen, XNCR On Watch, Results MAGNIFY CELG's R2 Regimen"

Advertisement
Quick Search
Advertisement
Advertisement